Samsung Medical Center Ranked No.1 in Asia-Pacific for Cancer, Respiratory, and Gastroenterology by Newsweek
Newsweek’s ‘2026 Asia-Pacific Best Specialty Hospitals’ Evaluation
Three Years Running at No.1 in Cancer and Respiratory, First-Ever Top Spot in Newly Added Gastroenterology
Seungwoo Park: “A Result of Specialization in Severe and Complex Diseas
Samsung Medical Center has been named the top specialty hospital in the Asia-Pacific region in three areas: cancer, respiratory, and gastroenterology. In particular, in the field of cancer, the hospital maintained its top ranking among general hospitals worldwide for the third consecutive year in the Asia-Pacific, following last year’s global ranking where it was rated highest among general hospitals outside of U.S. specialty hospitals.
Medical staff including Professor Lee Kyungjong from the Department of Pulmonology (third from the left in the photo) and the robotic bronchoscopy equipment operated by Samsung Medical Center. Samsung Medical Center
Photo by Samsung Medical Center
According to Newsweek, a U.S. weekly magazine, on June 18, Samsung Medical Center ranked first in the ‘2026 Asia-Pacific Best Specialty Hospitals’ evaluation in the three categories of cancer, respiratory, and gastroenterology. The evaluation was conducted by Newsweek in partnership with the German research firm Statista, based on reputation surveys of medical professionals from 11 countries including Korea, Japan, Australia, Taiwan, Singapore, and Thailand, along with national medical accreditation status and patient-reported outcome measures (PROMs). The evaluation covered ten specialties: cancer, respiratory, gastroenterology, cardiovascular, endocrinology, neurology, orthopedics, pediatrics, cardiac surgery, and neurosurgery, with gastroenterology added for the first time this year.
Samsung Medical Center has maintained its number one position in cancer and respiratory medicine for three consecutive years since 2024. It also secured the top spot in gastroenterology, which was evaluated for the first time this year, sweeping all three categories.
Seungwoo Park, president of Samsung Medical Center, stated, “This achievement is the result of focusing on severe and complex diseases and enhancing the quality of research and clinical care. We will continue to take on challenges toward the future of medicine.”
Five-Year Cancer Survival Rate of 75.4%... World’s Highest Among General Hospitals
In the field of cancer, Samsung Medical Center ranked third in last year’s Newsweek global specialty hospital ranking. With MSK and MD Anderson, both U.S. cancer specialty hospitals, holding the first and second spots, Samsung Medical Center was the top general hospital globally.
In 2008, Samsung Medical Center opened the largest cancer hospital in Asia in a single building. It was the first in Korea to introduce CAR-T cell therapy and is also implementing precision cancer treatment for patients without standard therapies. The five-year survival rate for all cancer patients treated at the Cancer Hospital is 75.4%.
Beyond improved treatment outcomes, the hospital is committed to enhancing patients’ quality of life. In June 2024, it established the ‘Cancer Patient Quality of Life Research Institute’ in collaboration with Samsung Fire & Marine Insurance. Starting that year, the hospital has been co-hosting bi-monthly patient-reported outcome (PRO) seminars with Charité Hospital in Germany. It has also signed a memorandum of understanding (MOU) with the European Organisation for Research and Treatment of Cancer (EORTC) for the standardization and quality management of the Korean translation of PRO tools, and received certification from ICHOM, a non-profit that sets international standards for patient-centered value-based healthcare (VBHC).
Five-year relative survival rates by cancer type featured in the 2026 Outcomes Book published this year by Samsung Medical Center Cancer Hospital. Samsung Medical Center
View original imageThree Consecutive Years at No.1 in Respiratory Care... Lung Cancer Survival Rate at 65.7%
Samsung Medical Center has ranked first in Asia-Pacific in respiratory medicine for three consecutive years. Last year, it held the highest global ranking among Korean hospitals at 19th place.
The hospital performs about 1,500 lung cancer surgeries per year on average, with over 90% conducted using minimally invasive techniques such as robotic and video-assisted thoracoscopic surgery. The 30-day postoperative mortality rate is just 0.1%. The survival rate for lung cancer patients at Samsung Medical Center is 65.7%, significantly higher than the Korean average of 42.5% and the U.S. average of 28.1%. The hospital has also developed the ‘RADAR CARE’ model, which predicts recurrence in early-stage non-small cell lung cancer one year in advance.
For diagnosing lung cancer, the pulmonology department performs over 1,600 endobronchial ultrasound (EBUS) procedures annually, with the cumulative total nearing 20,000. In March, the hospital introduced robotic bronchoscopy, allowing access to small lung nodules via robotic catheter, enabling diagnosis of nodules that were previously hard to reach with conventional methods.
In chronic obstructive pulmonary disease (COPD), Samsung Medical Center became the first hospital in Korea in 2022 to implement mobile-based PRO surveys for all COPD patients. For severe cases, it operates a 365-day monitoring program. The hospital is also in the final stages of developing an artificial intelligence (AI) model—supported by the Samsung Future Technology Development Program—that predicts lung function decline and exacerbation risk using only patients’ voices.
Professor Hongkwan Kim, Department of Thoracic and Esophageal Surgery at Samsung Medical Center, during lung cancer surgery using thoracoscopy (second from the left in the photo). Samsung Medical Center
Photo by Samsung Medical Center
First in Gastroenterology Evaluation... 0% Mortality for Esophageal Cancer Surgery
Samsung Medical Center also ranked first in gastroenterology, which was evaluated for the first time this year. The departments of gastroenterology, thoracic and esophageal surgery, gastrointestinal surgery, hepatobiliary-pancreatic surgery, and colorectal surgery collaborate in a multidisciplinary approach to treat diseases of the esophagus, stomach, colon, liver, pancreas, and gallbladder.
Esophageal cancer is regarded as the hospital’s leading specialty. In 2023, the hospital treated 22.2% of Korea’s 3,142 esophageal cancer patients. In 2025, out of 245 esophageal cancer surgeries, 219 (89.3%) were performed minimally invasively, with a 0% mortality rate within 30 days post-surgery and during hospitalization. The five-year relative survival rate for esophageal cancer patients is 62.5%, far surpassing the Korean average of 43.5% and the U.S. average of 21.9%.
The five-year relative survival rate for pancreatic cancer—a disease with typically poor outcomes—also reached 24.6%, higher than the Korean average of 17% and the U.S. average of 13.3%. In gastric cancer, the hospital was the first in the world in 2019 to prove the effectiveness of genome analysis-based personalized treatment, and treats over 700 early-stage gastric cancer cases annually using endoscopy.
For liver and colorectal cancer patients for whom standard treatment is difficult, the hospital is applying proton therapy. Having introduced a proton therapy system at the end of 2015, it became the first in Korea to surpass 2,000 liver cancer proton therapy cases as of September 2024. In colorectal cancer, the hospital provides proton therapy to more than 30 patients annually with inoperable liver metastases or recurrent pelvic rectal cancer.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Professor Sungno Hong, Department of Gastroenterology, Samsung Medical Center, preparing for a colonoscopy. Samsung Medical Center
View original image© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.